Human thrombomodulin significantly inhibited the rate of prothrombin conversion to thrombin by Factor X. in the presence of phospholipid or platelets, calcium, and Factor V.. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of 1"I-prothrombin activation revealed that thrombomodulin reduced the rate of prothrombin activation but did not alter the cleavage pattern. The inhibition was reversed by the inclusion of a highly specific rabbit antithrombomodulin antibody. If thrombomodulin was replaced by hirudin, the rate of thrombin generation was not decreased excluding the possibility that the inhibition by thrombomodulin was secondary to the binding of small amounts of thrombin formed early in the reaction and the prevention of feedback breakdown of prothrombin by thrombin. The inhibitory activity of thrombomodulin was overcome by increasing the concentration of Factor X. and specific, saturable binding of thrombomodulin to Factor X. was demonstrated. These results indicate that thrombomodulin binds to Factor X. and thereby inhibits the activity of the prothrombinase complex.
Introduction
Hemostasis is a complex process requiring strict regulation of plasma and cellular proteins for normal function. The formation of thrombin, from the prothrombinase complex, and its subsequent actions, is a focal point in this process (1) . The active enzyme in this complex is Factor Xa, which converts prothrombin to thrombin in the presence ofcalcium and lipid or a suitable surface (platelet or endothelial cells) (1, 2) .
Thrombomodulin is an endothelial cell receptor for thrombin (3) (4) (5) and it has been well established that thrombin's procoagulant activities such as the clotting of fibrinogen, platelet activation, and the activation of Factor V, are inhibited by complex formation with thrombomodulin (6) (7) (8) . Thrombin, when complexed to thrombomodulin, has over 1,000-fold greater ability to activate protein C when compared with thrombin alone (5) . Activated protein C (APC)' functions as a potent natural anticoagulant, inactivating Factors Va (9, 10) and VIIIa (1 1, 12). 1 . Abbreviations used in this paper: APC, activated protein C; NP40, Nonidet P-40; PRP, platelet-rich plasma; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
We recently observed that thrombomodulin inhibits thrombin inactivation of protein S (an important cofactor in the inactivation of Factors Va and VIIIa by APC) (unpublished observations). Thrombin may thus facilitate or, when complexed with thrombomodulin, inhibit the coagulation reaction.
Most published studies on thrombomodulin have focused on its interaction with thrombin. In this report, we examine the effect of thrombomodulin on the ability of Factor Xa to activate prothrombin.
Methods

Materials
Chemicals were purchased from the following suppliers: hirudin, heparin (sodium salt), dithiothreitol, tris, ammonium persulfate and bovine serum albumin (BSA) (Sigma Chemical Co., St. Louis, MO), calcium chloride, sodium chloride and glycine (Ajax Chemicals, Australia), platelin (General Diagnostics, Morris Plains, NJ), acrylamide (Bio-Rad Laboratories Co., Richmond, CA), sodium dodecyl sulfate and iodogen (Pierce Chemical Co., Rockford, IL), nonidet (NP40) (BDH Chemicals Ltd., Poole, England) and i-Phe-pipecolyl-Arg-p-nitroanilide (S2238) (Kabi Diagnostics, Stockholm, Sweden).
Procedures
All proteins used were of human origin. Prothrombin (13), Factor X (14), Factor V (15), thrombin (14) , and antithrombin III (16) were purified and/or activated as indicated. Thrombomodulin was prepared by a modification of the previously published procedure (17) , replacing the DEAE-Sepharose chromatography by a second diisopropyl fluorophosphate thrombin affinity chromatography as described.
Washed platelets were prepared from whole blood collected into 1/10 vol of4% disodium EDTA. Platelet-rich plasma (PRP) was obtained by centrifugation at 200 g for 15 min. A platelet pellet was prepared from PRP by centrifugation at 700 g for 10 min. Platelets were washed three times in 20 mM tris buffer, pH 7.4, containing 150 mM NaCl, 5 mM glucose, 6 mM EDTA, and finally resuspended in the same buffer without EDTA.
Prothrombin was labeled with 125I-Na (Amersham International, Buckinghamshire, England) using the "iodogen" method (following the manufacturer's instructions). Protein was separated from free iodide on a prepoured Sephadex G-25 column (Pharmacia Fine Chemicals, Uppsala, Sweden). Labeled prothrombin had a specific activity of 3,200 cpm/ng. Sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) was performed by the method of Laemmli (18) using 4% stacking gel and 10% acrylamide in the running gel. Samples were reduced by boiling in the presence of 0.5% dithiothreitol for 5 min. After electrophoresis, the gel was fixed, stained with Coomassie Brilliant Blue, dried, and autoradiographed.
Prothrombin activation by Factor X0. Prothrombin (1.4 gM) was incubated at 37°C in the presence ofphospholipid (platelin was prepared according to the manufacturer's instructions and using 100 IA/ml incubation mixture), calcium chloride (10 mM) and Factor Xa (0.05-10 nM). The reaction mixture was adjusted to a final volume of 1 ml using 20 mM tris buffer, pH 7.4, containing 0.15 M NaCl and 5 mg/ml BSA. Aliquots (50 z1) were removed at various time intervals and the amount of thrombin formed assayed by measuring the rate of hydrolysis of the chromogenic substrate S2238. The amidolytic reaction (600 Al) contained 0.2 mM S2238 in the buffer described above. The concentration of thrombin formed was determined by reference to a standard curve constructed using known amounts of thrombin.
Thrombin generation in the presence of thrombomodulin was evaluated by adding thrombomodulin (prepared in 20 mM tris/100 mM NaCI/0.2% NP40 buffer, pH 7.4) or an equal volume oftris/NaCl/NP40 control buffer to the incubation mixture.
In some experiments, Factor Va was included in the incubation and/ or platelin was replaced with washed platelets.
Antithrombomodulin antibody was obtained from a rabbit immunized with 60 Mg thrombomodulin injected at multiple intradermal sites. The antithrombomodulin IgG was isolated from the rabbit antiserum using protein A-Sepharose.
Factor Xa binding to thrombomodulin. Microtiter plates (Flow Laboratories, Zwanenburg, The Netherlands) were coated with 50 Ml ofFactor Xa (80 nM) in 0.1 M NaHCO3 buffer, pH 8.3, at 4°C for 16 h. The wells were then blocked with 20 mM tris buffer, pH 7.4, containing 50 mM NaCI and 5 mg/ml BSA for 1 h at 37°C. Thrombomodulin (50 ,ul) at a final concentration between 30 nM and 550 nM (or buffer as control) was added to the wells and incubated for 1 h in the presence or absence of thrombin (50 MM). After washing with 20 mM tris buffer, pH 7.4, containing 50 mM NaCl and 0.2% NP40, the wells were incubated with 50 MI culture supematant from hybridoma cells secreting an antithrombomodulin monoclonal antibody. Control experiments were also performed using culture supernatant from an antiprotein S hybridoma line.
After 1 h at 37°C, the plates were thoroughly washed with the tris/ NP40 buffer and 50 Ml (500,000 cpm/well) of 1251-goat anti-mouse IgG (Biorad, Sydney, Australia; affinity purified and labeled by the chloramine T method to a specific activity of 4,800 cpm/ng) was added. The plate was incubated at 37°C for 1 h, washed and the '251-antibody remaining on the plate quantitated (LKB gamma counter, Stockholm, Sweden).
Nonspecific binding was determined by the inclusion of a 100-fold molar excess of unlabeled Factor Xa (8 MuM) and the specific binding was calculated by deducting the nonspecific from the total binding.
Results
The activation of purified prothrombin (1.4 ,M) by Factor Xa (0.05 nM) in the presence of Factor Va (0.07 nM), calcium and phospholipids is shown in Fig. 1 . After a slight lag period, a rapid formation of thrombin amidolytic activity is observed at a rate of 1,000 mol thrombin/mol Factor Xa per min, with all the prothrombin being converted to thrombin after 90 min. Inclusion of thrombomodulin (8 nM) in the incubation mixture produced a significant inhibition in the rate ofthrombin generation to 125 mol thrombin/mol Factor Xa per min. Fig. 2 shows the effects of different thrombomodulin concentrations on the rate of prothrombin activation. In this experiment, Factor Va was excluded and Factor Xa was used at a concentration of 0.5 nM to obtain a rate of prothrombin activation similar to that in Fig. 1 . Only a slight inhibition ofthrombin formation was obtained with thrombomodulin values of 0.4 nM or less while concentrations of 1.6 nM thrombomodulin produced >90% inhibition.
The activation products obtained upon Factor Xa action on '251-prothrombin were analyzed by SDS-PAGE (Fig. 3) . In the absence of thrombomodulin, the proteolysis of the '251-prothrombin was almost complete by 90 min with the formation of thrombin via two major intermediates, prothrombin to thrombomodulin and not a minor contaminant in the preparation, the effect of a rabbit antithrombomodulin antibody was examined. This antibody is highly specific for thrombomodulin as previously reported. Fig. 4 shows that the inclusion of the antibody reduced the inhibitory activity of thrombomodulin on prothrombin activation. A higher concentration of antithrombomodulin IgG completely blocked the ability ofthrombomodulin to inhibit thrombin formation (data not shown). Control IgG, on the other hand, had no effect. These studies confirm that the inhibition of prothrombin cleavage is in fact related to thrombomodulin. Thrombomodulin forms a 1:1 molar complex with thrombin. The effects ofthrombomodulin on prothrombin activation could be related to the binding and subsequent inactivation of small amounts of thrombin formed early in the course of the reaction TIME (MINUTES) binding of the small amounts of thrombin formed early in the course of the reaction. On the other hand, ifantithrombin III (0.82 uM) and heparin (0.28 U/ml) were included (inhibiting both thrombin and Factor Xa), total inhibition of prothrombin conversion is observed similar to that obtained with high concentrations of thrombomodulin.
Effect ofincreasing Factor Xa concentration on the inhibition of thrombin generation by thrombomodulin. Thrombin generation was measured following a 60-min incubation of prothrombin with various Factor Xa concentrations in the presence or absence of thrombomodulin. The inhibition by thrombomodulin was expressed as a percentage of the control. Fig. 6 shows that thrombomodulin inhibitory activity decreased as the concentration of the enzyme Factor Xa was increased. In the experiment, thrombomodulin was used at a concentration of 8 nM and it can be seen that maximum thrombomodulin inhibition was obtained at Factor Xa concentrations < 2.0 nM while only 2% inhibition was found when 10 nM Factor Xa was used.
Factor Xa binding to thrombomodulin. The finding that thrombomodulin inhibition of prothrombin activation is decreased as the concentration ofFactor Xa increased suggests that thrombomodulin exerts its inhibitory activity via binding to Factor Xa. Fig. 7 demonstrates that indeed thrombomodulin (50-550 nM) binds to Factor Xa (80 nM) and the binding is specific and saturable. When Factor X instead of Factor Xa was used, no binding could be demonstrated and similarly, specific binding was not observed when the culture supernatant containing antithrombomodulin antibody was replaced with supernatant from an anti-protein S hybridoma line.
To determine the relationship between the Factor Xa and thrombin binding sites on thrombomodulin, binding studies were performed in the presence of 100-fold molar excess ofthrombin.
Inhibition ofFactor Xa,, by Thrombomodulin As shown in Fig. 7 Thrombomodulin could bind to prothrombin or an intermediate ofprothrombin activation and block further cleavage.
This mechanism is also unlikely since the experiments performed used a 100-fold molar excess of prothrombin to thrombomodulin. Furthermore, analysis of prothrombin activation products by SDS-PAGE showed no alteration in the cleavage pattern nor accumulation of the intermediates, prothrombin 1.2 or prethrombin 2 in the presence of thrombomodulin.
The inhibitory effect ofthrombomodulin could be secondary to binding of small amounts of thrombin formed early in the course ofthe reaction and prevention offeedback autocatalysis ofprothrombin by thrombin. This possibility was excluded since inclusion of hirudin, a specific thrombin inhibitor, did not alter prothrombin activation by Factor Xa (Fig. 7) . Furthermore, cleavage of prothrombin by thrombin, in concentrations up to 10 U/ml (100 nM), could not be demonstrated under the experimental conditions used (data not shown).
Thrombomodulin could bind Factor Xa in a manner that prevents the protease from binding to or cleaving prothrombin. Thrombin and Factor Xa are structurally similar with sequence homology between the A-chain of thrombin and the ,B form ofthe heavy chain of Factor Xa, both containing the active site amino acid residues-serine, histidine, aspartic acid, and aspartic acid in homologous positions (1, 20) . It 
